NASDAQ: AZN
Astrazeneca Plc Stock

AZN Price
$51.07
Fair Value Price
N/A
Market Cap
$134.01B
52 Week Low
$37.79
52 Week High
$61.10
P/E
62.28x
P/B
10.95x
P/S
5.4x
PEG
1.11x
Dividend Yield
2.74%%
Revenue
$25.70B
Earnings
$2.05B
Gross Profit Margin
80%%
Operating Margin
15.21%%
Net Profit Margin
8%%
Debt to Equity
3.78
Operating Cash Flow
$5B
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
32
Industry average

Reasons for this score

AZN ($51.07) is trading below its intrinsic value of $154.43, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
AZN is poor value based on its earnings relative to its share price (62.28x), compared to the US market average (46.84x)
Valuation
AZN is good value based on its earnings relative to its share price (62.28x), compared to the US Drug Manufacturers - General industry average (-11.04x)
Valuation

1 of 13

AZN News

Valuation

AZN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
62.28x
Industry
-11.04x
Market
46.84x
AZN is poor value based on its earnings relative to its share price (62.28x), compared to the US market average (46.84x)
Valuation
AZN is good value based on its earnings relative to its share price (62.28x), compared to the US Drug Manufacturers - General industry average (-11.04x)
Valuation

AZN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
10.95x
Industry
7.13x
Market
63.22x
AZN is good value based on its book value relative to its share price (10.95x), compared to the US market average (63.22x)
Valuation
AZN is poor value based on its book value relative to its share price (10.95x), compared to the US Drug Manufacturers - General industry average (7.13x)
Valuation

AZN price to earnings growth (PEG)

For valuing profitable companies with growth potential
AZN is poor value relative to its rate of earnings growth, measured by PEG ratio (1.11x)
Valuation

AZN's financial health

Profit margin

Revenue
$6.7B
Net Income
$277.0M
Profit Margin
4.2%%
AZN's Earnings (EBIT) of $3.91B are insufficient to safely cover interest payments on company debt ($19.75B)
Financials
AZN's profit margin has decreased (-1%%) in the last year from (9%%) to (8%%)
Financials

Assets to liabilities

Assets
$61.4B
Liabilities
$46.8B
Debt to equity
1.39
AZN's short-term liabilities ($18.18B) exceed its short-term assets ($14.93B)
Financials
AZN's long-term liabilities ($28.09B) exceed its short-term assets ($14.93B)
Financials
AZN's debt has increased relative to shareholder equity (3.78), over the past 5 years ago (2.02)
Financials
AZN's debt to equity ratio (3.78) is considered high
Financials

Cash flow

Operating
$4.9B
Investing
-$657.0M
Financing
-$1.8B
AZN's operating cash flow ($4.86B) is sufficient to service the company's debt ($19.75B)
Financials

Astrazeneca Stock FAQ

(NASDAQ: AZN) Astrazeneca trades on the NASDAQ under the ticker symbol AZN. Astrazeneca stock quotes can also be displayed as NASDAQ: AZN.
(NASDAQ: AZN) Astrazeneca stock price per share is $51.07 today (as of Oct 29, 2020).
(NASDAQ: AZN) Astrazeneca's 52-week high was $61.10, and its 52-week low was $37.79. It is currently -16.42%% from its 52-week high and 35.14%% from its 52-week low.
(NASDAQ: AZN) Astrazeneca's market cap is $134.01B, as of Oct 30, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Astrazeneca's market cap is calculated by multiplying AZN's current stock price of $51.07 by AZN's total outstanding shares of 1,312,000,000.
(NASDAQ: AZN) Astrazeneca currently has 1,312,000,000 outstanding shares. With Astrazeneca stock trading at $51.07 per share, the total value of Astrazeneca stock (market capitalization) is $134.01B.

Astrazeneca stock was originally listed at a price of $18.00 in Dec 31, 1997. If you had invested in Astrazeneca stock at $18.00, your return over the last 22 years would have been 183.72%%, for an annualized return of 4.85%%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics